logo

For the Inventor, By the Inventor

Osaka, Japan

Anges Mg, Inc.

USPTO Granted Patents = 29

% Expired Patents = 31.0



Forward Citations = 114

Loading Chart...
Loading Chart...

63 inventors (with patents filed for the assignee):

goldMedal Ryuichi Morishita (21 out of 47 patents)

silverMedal Yasufumi Kaneda (11 out of 25 patents)

bronzeMedal Toshio Ogihara (8 out of 9 patents)

4.  Motokuni Aoki (5 out of 5 patents)

5.  Hitoshi Kotani (4 out of 4 patents)

6.  Takefumi Gemba (3 out of 9 patents)

7.  Hironori Nakagami (2 out of 18 patents)

8.  Takashi Miyake (2 out of 14 patents)

9.  Akiko Tenma (2 out of 10 patents)

10.  Hideki Tomioka (2 out of 9 patents)

11.  Nao Tamura (2 out of 4 patents)

12.  Tomio Kawasaki (2 out of 2 patents)

13.  Kuniaki Nakanishi (2 out of 2 patents)

14.  Seiji Yamamoto (2 out of 2 patents)

15.  Tadashi Tanabe (1 out of 6 patents)


Core Competencies:
DNA Vaccine
Drug-Eluting Catheter
Topical Administration
Antibacterial Activity
Angiogenesis
Pharmaceutical Compositions
Hepatocyte Growth Factor
Gene Transfer
Skin Ulcers
Cancer Treatment
Cerebrovascular Disorders
Auditory Dysfunction

29 patents:

1. 9446120 - DNA vaccine (2016-09-20),
2. 9186439 - Drug-eluting catheter and method of manufacturing the same (2015-11-17),
3. 9012417 - Topical administration of NF-kappaB decoy to treat atopic dermatitis (2015-04-21),
4. 8969311 - Polypeptide having antibacterial activity and angiogenesis-inducing activity and wound-healing drug containing said polypeptide (2015-03-03),
5. 8647820 - Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription (2014-02-11),
6. 8470765 - Polypeptides and antibacterial or antiseptic use of same (2013-06-25),
7. 8067388 - Decoy-containing pharmaceutical compositions and method of using the same (2011-11-29),
8. 8067384 - Chimera (double) decoy (2011-11-29),
9. 7994151 - Compositions and methods for angiogenic therapy utilizing genes encoding ets-1 (2011-08-09),
10. 7939504 - Method of treating skin ulcers with vectors encoding hepatocyte growth factor (2011-05-10),
11. 7871983 - Remedy and preventive for diseases caused by NF-κB (2011-01-18),
12. 7871765 - Composition having antitumor effect (2011-01-18),
13. 7803621 - Virus envelope vector for gene transfer (2010-09-28),
14. 7790692 - Hepatocyte growth factor nucleic acid sequence to enhance musculocutaneous flap survival (2010-09-07),
15. 7763591 - Hepatocyte growth factor gene therapy for parkinson's disease (2010-07-27),
Company Overview
Anges Mg, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of innovative gene therapies and advanced medical solutions. The organization focuses on harnessing cutting-edge research in genetic engineering and regenerative medicine to address unmet medical needs. With a commitment to improving patient outcomes, Anges Mg is actively engaged in the research and development of novel therapeutic approaches, leveraging its expertise to contribute to the evolving landscape of healthcare.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

29 Patents

#249 in Osaka

#2,362 in Japan

#22,570 in the World

Osaka, JP
Osaka, Japan

Anges Mg, Inc.

Forward Citations = 114

63 inventors:

goldMedal Ryuichi Morishita (21 out of 47 patents)

silverMedal Yasufumi Kaneda (11 out of 25 patents)

bronzeMedal Toshio Ogihara (8 out of 9 patents)

4.  Motokuni Aoki (5 out of 5 patents)

5.  Hitoshi Kotani (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Anges Mg, Inc.. Retrieved from https://idiyas.com/company/anges-mg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…